House Passes Bill to Limit Insulin Co-Pays, but the Way Forward in Senate Is Unclear

Senate Majority Leader Chuck Schumer (D-N.Y.)
Senate Majority Leader Chuck Schumer (D-N.Y.) said last month "the Senate will vote on a bill to fix" the skyrocketing cost of insulin. The House last week passed a bill limiting cost-sharing for insulin.

The U.S. House passed a bill late last week limiting cost-sharing for insulin under private health insurance and Medicare Part D.

H.R. 6833 caps cost-sharing under private health insurance for a month’s supply of selected insulin products at $35 or

Read More »

CMS Projects that Drug Spending and Drug Prices Will Keep Rising Through 2030

graphic image of pills and $ on a scale
CMS predicts that U.S. retail prescription drug spending will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

The Centers for Medicare & Medicaid Services (CMS) Office of the Actuary

Read More »

Next Month’s 340B Registration Period Overlaps with Deadline for Hospitals Seeking Reinstatement

arrows pointing to Registration
The Q2 2022 registration period for 340B overlaps with the April 14 deadline for hospitals that lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork for reinstatement.

The next period for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, April 1, and end on Friday, April 15.

Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during

Read More »

News Alert

HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy

Boehringer Ingelheim exterior sign and building
HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.

The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”

HRSA told BI in a March 29

Read More »

HRSA Invokes Contract Pharmacy Fight in Pitch for Comprehensive 340B Regulatory Power

Department of Health and Human Service budget title page
HRSA yesterday told Congress in its budget request that it needed comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program.

Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did

Read More »

Arkansas Health Centers and Community Hospital Want Role in Challenging PhRMA’s Lawsuit Over State’s Novel 340B Contract Pharmacy Law

Entrance to Mid Delta Health Center
Mid Delta Health Center is a member of Community Health Centers of Arkansas, which wants to intervene in PhRMA's lawsuit challenging the state's one-of-a-kind law protecting 340B contract pharmacy arrangements.

Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.

Community Health Centers of Arkansas (CHCA) filed the motion yesterday along with

Read More »

BioComp Providing Refunds for 340B Overcharges Spanning a Whopping 8 Years

BioComp Pharma product list
Following a HRSA audit, BioComp Pharma is offering 340B covered entities refunds on six products for overcharges spanning eight years.

Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.

BioComp, a wholly-owned subsidiary of San

Read More »

Feds Take Over Prosecution of Whistleblower Suit Against Tenn. Health System Alleged to Have Paid Cancer Docs Illegally for Referrals that Boosted 340B Profits

Methodist University hospital building
The federal government has decided to intervene in a 340B-related whistleblower lawsuit involving Methodist University Hospital in Memphis, Tenn.

The federal government has decided to intervene in a whistleblower lawsuit that accuses a Tennessee health system of paying Memphis-area cancer physicians for referrals that allegedly generated about $70 million a year in profits for the health system from billings

Read More »

California 340B Health Centers Say State “Essentially Admits” Flaws in Medicaid Drug Reimbursement Change

Sherman Heights Family Health Center building
California health centers want a federal court to stop a state Medicaid policy that deprives them of millions of dollars in 340B drug reimbursement.

California health centers told a federal judge last week that the state’s arguments for dismissing the centers’ lawsuit to reverse a new state Medicaid policy that deprives them of millions of dollars in 340B drug reimbursement lack merit.

Community Health

Read More »

News Alert

HRSA Starts Contacting Hospitals Forced Out of 340B During Pandemic About Possible Reinstatement

Dept. of Health and Human Services exterior sign and building
HRSA will review and release some of the 340B-related records the New York Times is seeking through FOIA requests.

UPDATE Friday, March 18, 2022, 1:30 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) told 340B Report shortly after this story was published, “To be eligible, [a] hospital’s termination must have been as a result of actions taken by

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live